title: [Resistance to antibiotics of Streptococcus pneumoniae strains].
abstract: Streptococcus pneumoniae strains are exhibiting increasing rates of antibiotics resistance. A rapid increase of resistance was seen not only to penicillin but also other antimicrobial agents and therefore this paper describes the study of resistance and multiresistance of pneumococci to 7 antibiotics: penicillin (P), erythromycin (E), clindamycin (CC), tetracycline (T), co-trimoxazole (SXT), cefotaxime (CTX) and vancomycin (Va), using the disk-diffusion technique according to NCCLS procedure. We tested a total of 218 S. pneumoniae strains isolated from various materials: from sputum (54), noses (117), throats (28) and different swabs specimens (19). The overall percentage of resistant isolates to penicillin was 3.7%, to erythromycin--4.1%, to clindamycin--10.6%, to tetracycline--17.4%, to co-trimoxazole--15.6%, to cefotaxime--2.3%. In the sputum was most the monoresistant strains (66.7%). The multiresistance was highest in the penicillin resistant pneumococci. With the exception of vancomycin, the number of resistant strains to non-beta-lactam antibiotics (erythromycin, clindamycin, tetracycline, co-trimoxazole) was higher in penicillin-resistant strains compared with penicillin susceptible isolates. All isolates were susceptible to vancomycin.
authors.affiliation: Katedra i Zakład Mikrobiologii Akademii Medycznej w Bydgoszczy.
authors.forename: G
authors.initials: G
authors.lastname: Janicka
authors.forename: A
authors.initials: A
authors.lastname: Mikucka
authors.forename: M
authors.initials: M
authors.lastname: Białek
authors.forename: E
authors.initials: E
authors.lastname: Gospodarek
authors.forename: I
authors.initials: I
authors.lastname: Kania
authors.forename: B
authors.initials: B
authors.lastname: Rózycka
authors.forename: D
authors.initials: D
authors.lastname: Krawiecka
authors.forename: I
authors.initials: I
authors.lastname: Wojak
authors.forename: E
authors.initials: E
authors.lastname: Kruszyńska
mesh_terms: D000328:Adult; D002439:Cefotaxime / Q000494:pharmacology; D002648:Child; D002981:Clindamycin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D009666:Nose / Q000382:microbiology; D010403:Penicillin Resistance; D010614:Pharynx / Q000382:microbiology; D013045:Species Specificity; D013183:Sputum / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000187:drug effects*; D013752:Tetracycline / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D002981:Clindamycin; D004917:Erythromycin; D014640:Vancomycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013752:Tetracycline; D002439:Cefotaxime
vernacular_title: Oporność na antybiotyki szczepów Streptococcus pneumoniae.